Navigation Links
Echo Therapeutics Achieves ISO 13485 Certification
Date:3/15/2013

PHILADELPHIA, March 15, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced that it has been granted International Standards Organization (ISO) 13485:2003 certification of its quality management system, an internationally recognized quality standard for medical devices.

(Logo: http://photos.prnewswire.com/prnh/20120801/NE50071LOGO )

ISO 13485:2003 is an internationally recognized standard that prescribes consistent processes for the development, design and manufacturing of medical devices.  Certification to the ISO 13485 standard represents an important step toward attaining European CE Mark approval for the Company's break-through technology.

"This achievement demonstrates Echo's continued commitment to meeting and exceeding the high standards required of medical device companies selling into Europe," said Stephen Perez , Echo's Vice President of Quality Assurance. "We believe that receiving ISO 13485 certification is a significant accomplishment and an important milestone as we approach the European pivotal trial and commercialization of our Symphony CGM System."

About Echo Therapeutics
Echo Therapeutics is developing the Symphony CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system.  Our target is patients who could benefit from glucose monitoring in the hospital setting, including critical care.  Significant opportunity also exists for patients with diabetes to use Symphony in the outpatient setting.  Echo is also developing its needle-free skin preparation component of Symphony, the Prelude® SkinPrep System, as a platform technology to enhance drug delivery of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements
The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's ongoing studies, including the safety and efficacy of Echo's Symphony CGM System, the failure of future development and preliminary marketing efforts related to Echo's Symphony CGM and Prelude SkinPrep Systems, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony CGM and Prelude SkinPrep Systems, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony CGM and Prelude SkinPrep Systems. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2011, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.

For More Information:
Christine H. Olimpio                                         
Director, Investor Relations and Corporate Communications
(215) 717-4104 
colimpio@echotx.com                                       

Connect With Us:
- Visit our website at www.echotx.com 
- Follow us on Twitter at www.twitter.com/echotx 
- Join us on Facebook at www.facebook.com/echotx


'/>"/>
SOURCE Echo Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
2. Echo Therapeutics Appoints Robert Doman to Board of Directors
3. Autoinjectors to 2018 Devices, Therapeutics, Markets, Strategies and Prospect
4. ADVENTRX Completes Name Change To "Mast Therapeutics, Inc."; New Ticker Symbol: "MSTX"
5. Cell Therapeutics to Present at the ROTH Capital Partners 25th Annual Growth Stock Conference
6. PTC Therapeutics Closes $60 Million Private Financing
7. Orexigen Therapeutics to Host Full Year and Fourth Quarter 2012 Financial Results Conference Call and Webcast
8. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
9. Todays Research on PDL BioPharma, Dendreon, Medivation, ACADIA Pharma, and Cell Therapeutics
10. Halozyme Therapeutics to Present at the Barclays 2013 Global Healthcare Conference
11. Relmada Therapeutics Announces LevoCap ER Development Progress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , March 29, 2017  The leader in ... that Drs. Sam Daher , Manal Ibrahim ... and David Couchat will be the featured microlecture presenters ... upcoming American Association of Orthodontists (AAO) Annual Session, April ... attend the microlectures beginning daily at 11:20 a.m. On ...
(Date:3/29/2017)... Texas , March 29, 2017  Maxor National ... today announced that it has named Leah Bailey ... for all divisions of the company. With ... including the previous 8 years focused on health care, ... During her tenure at Prime, Bailey advised the PBM, ...
(Date:3/29/2017)... JOSE, Calif. , March 29, 2017  Designers ... now significantly reduce solution size by 50% and extend ... Q ) power management integrated circuit (PMIC) from Maxim ... wearable PMIC supports a low input voltage of just ... Zinc Air and Silver Oxide, as well as the ...
Breaking Medicine Technology:
(Date:3/29/2017)... (PRWEB) , ... March 29, ... ... Manufacturer Alliance (GRMA) is growing as it continues developing an ANSI-approved, consensus-based ... industry. The organization, which plans to publish the first ANSI-approved GMP standard ...
(Date:3/29/2017)... ... March 29, 2017 , ... Curio Wellness , a premium ... finalization of the company’s executive management team with prominent executives from both inside and ... Wellness’ Chief Operating Officer, Ted Dumbauld , who has more than twenty years ...
(Date:3/29/2017)... ... March 29, 2017 , ... The assembly of synthetic ... involve many repetitive steps and often scientists require many different versions of DNA. ... and results in a lower error rate and cost saving for reagents and ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... have easier access to the robotic-assisted total-hip and partial-knee replacement surgeries that ... surgeons at Forbes Hospital and Jefferson Hospital recently started performing these surgeries ...
(Date:3/29/2017)... ... 2017 , ... AvePoint , the Microsoft Cloud expert, is pleased to ... located at the Riverfront Plaza, 901 East Byrd Street. AvePoint is celebrating with a ... Northam and Mayor of Richmond Levar M. Stoney. , Founded in 2001, AvePoint employs ...
Breaking Medicine News(10 mins):